Anzeige
Mehr »
Freitag, 27.06.2025 - Börsentäglich über 12.000 News
Blockbuster-Bohrergebnisse: Gold-Antimon-Fund in Nevada trifft geopolitischen Nerv
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2AC4K | ISIN: US28106W1036 | Ticker-Symbol: 8EM
Tradegate
26.06.25 | 17:09
1,843 Euro
+1,49 % +0,027
1-Jahres-Chart
EDITAS MEDICINE INC Chart 1 Jahr
5-Tage-Chart
EDITAS MEDICINE INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,9241,94416:50
1,9161,93516:50

Aktuelle News zur EDITAS MEDICINE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
17.06.Editas Medicine Is Great. Here's Why You Shouldn't Buy It.4
12.06.Editas Medicine, Inc. - 8-K, Current Report15
12.06.Editas Medicine, Inc.: Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology ...166Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy. Achievement...
► Artikel lesen
02.06.Editas Medicine ändert Aktienplan und erhöht genehmigte Aktien13
02.06.Editas Medicine, Inc. - 8-K, Current Report1
28.05.Editas Medicine, Cassava Sciences among healthcare stocks to join Russell Microcap; MNKD, OCGN to exit56
16.05.Editas Medicine: A Cautionary Tale for Investors7
14.05.Editas Medicine, Inc.: Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June2
EDITAS MEDICINE Aktie jetzt für 0€ handeln
14.05.Editas Medicine, Inc.: Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas' Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting175Data demonstrate therapeutically relevant editing levels using a clinically validated strategy, supporting its development as a novel, in vivo approach to treating sickle cell disease and beta thalassemia...
► Artikel lesen
13.05.Editas Medicine meldet Durchbruch bei der Behandlung von Lebererkrankungen16
13.05.Editas Medicine reports breakthrough in liver disease treatment3
13.05.Editas Medicine, Inc.: Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting126In vivo CRISPR Editing Results in Functional Upregulation of a Liver Target Protein and Meaningful Reduction of Disease-Associated Biomarker in Mice CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE)...
► Artikel lesen
13.05.Editas Medicine stock target cut to $4 at Evercore ISI3
12.05.Editas Medicine, Inc. - 10-Q, Quarterly Report1
12.05.Editas Medicine, Inc.: Editas Medicine Announces First Quarter 2025 Results and Business Updates367Company to share in vivo preclinical data demonstrating the successful use of targeted lipid nanoparticles to deliver HBG1/2 promoter editing cargo to hematopoietic stem and progenitor cells (HSPCs)...
► Artikel lesen
12.05.Editas Medicine, Inc. - 8-K, Current Report1
12.05.Editas zeigt sich optimistisch über CRISPR-Patentverfahren nach Berufung10
12.05.Editas Medicine, Inc.: Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board116CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced that the U.S. Court of Appeals for the Federal Circuit affirmed-in-part...
► Artikel lesen
28.04.Editas Medicine, Inc.: Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting11
21.03.AstraZeneca deepens China investment; Editas loses CFO to Dyne16
Weiter >>
38 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1